Ross Muken, Chief Executive Officer and Director of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on September 22, 2026, reporting the sale of 422 ordinary shares on September 21, 2026, to cover tax withholding obligations from a restricted stock unit vesting.

Key Highlights

  • Reporting person: Ross Muken, serving as Chief Executive Officer and Director of SOPHiA GENETICS SA
  • Transaction: 422 ordinary shares disposed of (transaction code S) on September 21, 2026, at $8.33 per share
  • Purpose: Shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units on September 18, 2026
  • Rule 10b5-1 plan: The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan and, according to the filing, "do not represent discretionary trades"
  • Remaining ownership: Following the transaction, Muken directly holds 670,229 ordinary shares

CEO Share Sale Tied to RSU Vesting at SOPHiA GENETICS

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Ross Muken sold 422 ordinary shares of SOPHiA GENETICS SA on September 21, 2026, at a price of $8.33 per share. The filing identifies Muken as both Chief Executive Officer and a Director of the company, which trades on NASDAQ:SOPH.

The filing states that the shares sold "represent shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on September 18, 2026." The transaction was carried out under a pre-established Rule 10b5-1(c) trading plan previously adopted by Muken. Following the reported sale, Muken's direct beneficial ownership stands at 670,229 ordinary shares, per the filing.

The Form 4 was signed by Elimara Brunetto as attorney-in-fact for Ross Muken and dated September 22, 2026. The filing also indicates that the box confirming a transaction made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan was checked.

What Was Disclosed

SOPHiA GENETICS SA CEO Ross Muken reported the open-market sale of 422 ordinary shares at $8.33 each on September 21, 2026, solely to cover tax withholding on vesting RSUs, executed under a pre-established Rule 10b5-1(c) plan, leaving him with 670,229 shares held directly.